- Home
- ENGN vs PRQR Comparison
ENGN vs PRQR Comparison
Compare ENGN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- PRQR
- Stock Information
- Founded
- ENGN 1999
- PRQR 2012
- Country
- ENGN Canada
- PRQR Netherlands
- Employees
- ENGN N/A
- PRQR N/A
- Industry
- ENGN
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- PRQR Health Care
- Exchange
- ENGN Nasdaq
- PRQR Nasdaq
- Market Cap
- ENGN 321.5M
- PRQR 232.8M
- IPO Year
- ENGN N/A
- PRQR 2014
- Fundamental
- Price
- ENGN $5.97
- PRQR $1.99
- Analyst Decision
- ENGN Buy
- PRQR Strong Buy
- Analyst Count
- ENGN 8
- PRQR 8
- Target Price
- ENGN $21.50
- PRQR $8.88
- AVG Volume (30 Days)
- ENGN 217.5K
- PRQR 378.7K
- Earning Date
- ENGN 09-11-2025
- PRQR 11-06-2025
- Dividend Yield
- ENGN N/A
- PRQR N/A
- EPS Growth
- ENGN N/A
- PRQR N/A
- EPS
- ENGN N/A
- PRQR N/A
- Revenue
- ENGN N/A
- PRQR $20,129,184.00
- Revenue This Year
- ENGN N/A
- PRQR N/A
- Revenue Next Year
- ENGN N/A
- PRQR N/A
- P/E Ratio
- ENGN N/A
- PRQR N/A
- Revenue Growth
- ENGN N/A
- PRQR 8.65
- 52 Week Low
- ENGN $2.65
- PRQR $1.07
- 52 Week High
- ENGN $11.00
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ENGN 72.82
- PRQR 37.36
- Support Level
- ENGN $5.52
- PRQR $2.21
- Resistance Level
- ENGN $6.54
- PRQR $2.50
- Average True Range (ATR)
- ENGN 0.53
- PRQR 0.15
- MACD
- ENGN 0.12
- PRQR -0.03
- Stochastic Oscillator
- ENGN 76.64
- PRQR 4.63
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.